Erdafixen 4mg (Erdafitinib) - Bladder Cancer Treatment

Name: Erdafixen 4mg (Erdafitinib): Targeted Treatment for FGFR-Altered Urothelial Cancer
Brand: Aio Pharma
SKU: 2241
Availability: InStock
Rating: 5 (1 reviews)

Erdafixen 4mg contains erdafitinib, a targeted oral therapy for adults with advanced or metastatic urothelial carcinoma (bladder cancer) that carries specific alterations in the FGFR gene — most often FGFR2 or FGFR3. It’s typically prescribed for patients whose cancer has continued to grow despite at least one prior round of chemotherapy.

Instead of attacking cells broadly the way chemotherapy does, erdafitinib works by blocking FGFR proteins that send growth signals to cancer cells. When these receptors are mutated or abnormally active, they can drive tumor growth unchecked — erdafitinib interrupts that signal, helping slow or stop disease progression in patients whose tumors carry these specific genetic changes.

Who is Erdafixen typically prescribed for?

Doctors generally reserve erdafitinib for patients with confirmed FGFR2/FGFR3 alterations, verified through a companion diagnostic test before treatment begins. It’s usually considered after standard chemotherapy has been tried and hasn’t worked well enough. As with any targeted cancer therapy, only an oncologist can confirm suitability based on genetic testing and overall health.

A few things patients should know

Regular eye exams are typically recommended during treatment, since this class of medication can affect vision in some patients. It’s also not suitable during pregnancy. Your prescribing doctor will walk you through monitoring and any precautions specific to your treatment plan.

Dosage Information

Standard starting dose: 8mg once daily, taken orally, with or without food
Dose may be adjusted upward to 9mg daily after 14–21 days based on blood phosphate levels and tolerability
If side effects occur, doctors reduce the dose in steps: 8mg → 6mg → 5mg → 4mg, per medical guidance
Tablets should be swallowed whole; do not crush or split
If a dose is vomited, do not take a replacement dose that day — resume the regular schedule the next day
Always follow the exact dosage and schedule prescribed by your treating physician — this is not a substitute for medical instructions

Frequently Asked Questions about Erdafixen 4mg

What is Erdafixen 4mg used for?

It's used to treat advanced or metastatic bladder cancer (urothelial carcinoma) in patients whose tumors have specific FGFR2 or FGFR3 gene alterations, confirmed through genetic testing.

Do I need a genetic test before taking this medicine?

Yes. An FDA-approved companion diagnostic test is required to confirm FGFR2/3 alterations before starting treatment, since the drug is only effective for this specific genetic profile.

What are the common side effects of Erdafitinib?

Commonly reported effects include dry mouth, elevated phosphate levels, nail changes, mouth sores, fatigue, and eye-related symptoms such as dry eyes. Regular eye exams are typically recommended during the first several months of treatment.

Can Erdafixen be taken during pregnancy?

No. It may cause harm to a developing fetus and is not recommended during pregnancy. Effective contraception is advised during treatment and for at least one month after stopping.

Is Erdafixen the same as the brand-name drug Balversa?

Erdafixen contains the same active ingredient, erdafitinib, offered as a more affordable alternative under WHO-GMP certified manufacturing standards.

How is Erdafixen different from chemotherapy?

Unlike chemotherapy, which affects healthy and cancerous cells broadly, Erdafixen specifically targets cancer cells with FGFR gene alterations, which can mean a more focused treatment approach for eligible patients.

Why patients and clinics choose Aio Pharma’s Erdafixen 4mg

Manufactured under WHO-GMP certified standards
Competitively priced compared to originator brands
Worldwide shipping with secure, discreet delivery

This description is for informational purposes only and does not replace medical advice. Always consult a licensed healthcare provider before starting or changing any cancer treatment.